Percutaneous coronary intervention (PCI) is commonly used in the surgical treatment of patients with various types of cardiac diseases. Some patients require long-term anticoagulation in the presence of deep vein thrombosis, atrial fibrillation and mechanical heart valves, and inappropriate anticoagulation during the perioperative period may lead to bleeding events or thrombotic events. In this paper, the importance of anticoagulation in the practical application of percutaneous coronary intervention (PCI) is first introduced, and then the various drug regimens used in the perioperative anticoagulation of percutaneous coronary intervention are explored in detail in the light of current research advances, with a view to providing guidance for clinical practice.
References
[1]
Yao, X. (2018) Efficacy of Combined Percutaneous Coronary Intervention (PCI) after Intravenous Thrombolysis (TT) Compared with Direct PCI for Acute Myocardial Infarction. Contemporary Medicine, 24, 3.
[2]
Ren, Z.H., Liu, Y.H., Zhang, S.L., et al. (2019) Study on the Efficacy and Safety of Bivalirudin and Heparin in Patients with Acute Coronary Syndrome with Chronic Kidney Disease Undergoing PCI. Hebei Medicine, 41, 4.
[3]
Zhao, Y.J., Peng, H.Y., Qin, Y.J., et al. (2018) Effect of Different Doses of Enoxaparin Combined with Tegretol after Percutaneous Coronary Intervention on Clinical Events in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome with Complex Coronary Artery Lesions. Chinese Journal of Interventional Cardiology, 26, 9.
[4]
Ran, C.G., Han, J. and Zhao, N. (2022) Efficacy and Prognostic Evaluation of Bivalirudin Combined with Salvage PCI in Elderly Patients with Failed Thrombolysis in Acute Myocardial Infarction. Journal of Clinical and Experimental Medicine, 21, 4.
[5]
Wang, Z.M., Zheng, H.J., Zeng, H., et al. (2021) Comparison of the Efficacy and Safety of Different Anticoagulation Strengths of Argatroban in Patients with Acute ST-Segment Elevation Myocardial Infarction at High Bleeding Risk with Percutaneous Coronary Intervention. Journal of Practical Medicine, 37, 5.
[6]
Zhu, L.R. (2019) Exploring the Efficacy and Safety of Antithrombotic Therapy with Dabigatranate Combined with Clopidogrel after Stenting with Percutaneous Coronary Intervention (PCI) in Patients with Atrial Fibrillation. World Abstract of the Latest Medical Information, No. 90, 2.
[7]
Zhao, N.N., Zhang, Y.D. and Zhang, P.P. (2020) Clinical Application of Rivaroxaban versus Warfarin on Adverse Cardiovascular Events after PCI Intervention in Patients with Atrial Fibrillation Combined with ACS. Liaoning Medical Journal, 34, 3.
[8]
Liu, H., Gao, B., Zhao, F., et al. (2018) Study of Anticoagulation Protocols for Patients Undergoing Further Non-Cardiac Surgery after PCI. Chongqing Medicine, 47, 3.
[9]
Wang, W.X. (2019) Advances in Anticoagulation Therapy in the Perioperative Period of Acute Coronary Syndrome PCI. Master’s Thesis, Chongqing Medical University, Chongqing.
[10]
Liu, X.Y., Liu, Y.M. and Shao, L. (2018) Analysis of the Effect of Different Anticoagulation Regimens on Periprocedural Anticoagulation in Patients with Unstable Angina Pectoris Undergoing PCI. Chinese Journal of Frontiers in Medicine (Electronic Version), 10, 98-101.
[11]
Li, C., Wang, G.H., Wang, J.Q., et al. (2020) Impact of Post-PCI Anticoagulation Therapy on Long-Term Prognosis in Patients with High Embolic Risk Atrial Fibrillation. Journal of Heart, 32, 5.
[12]
Guo, P.Y. (2019) Meta-Analysis of the Efficacy and Safety of New Oral Anticoagulants Used in Patients with Coronary Artery Disease Combined with Atrial Fibrillation Undergoing PCI. Master’s Thesis, Anhui Medical University, Hefei.
